France
FineHeart, a clinical stage medical device company based in Bordeaux, France, is making waves in the healthcare industry with its groundbreaking product, FLOWMAKER®. This innovative device has the potential to transform the lives of 200,000 patients suffering from advanced heart failure annually, addressing a market segment estimated to be worth over US$5 billion.
Founded in 2010 by CEO Arnaud Mascarell and a team of esteemed cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue and Dr. Philippe Ritter, FineHeart boasts an international portfolio of 147 patents in 25 different families, showcasing the company's commitment to innovation and intellectual property protection.
One of the key distinguishing factors of FLOWMAKER® is its status as the first fully intraventricular, wireless flow accelerator, providing synchronized physiological support without the need for aortic bypass surgery. Measuring a mere 10 cm in size, this miniaturized device can be tailored to meet the varying needs of patients, making it a significant advancement in heart failure treatment.
Furthermore, FineHeart has leveraged a diverse network of support from public, private, industrial, and independent investors, including renowned entities such as Lauak, Doliam, Aquiti, Broadview Ventures, Galia, and Bpifrance. With financial backing from the European Union (EIC) and several regional bodies, FineHeart has solidified its position as a formidable player in the medical technology landscape.
With its innovative approach and strong financial backing, FineHeart is poised to revolutionize heart failure treatment, offering hope and improved quality of life to patients globally.
